Overcome Analytical Method Validation. Top Challenges!

Size: px
Start display at page:

Download "Overcome Analytical Method Validation. Top Challenges!"

Transcription

1 Overcome Analytical Method Validation Top Challenges! December 8, 2015 Lina Patel, Ph.D. Director, Quality Operations Laboratories IVT s Lab Week Series Analytical Procedures and Methods Validation December 8-10, 2015 Philadelphia, PA 1

2 Overview Strategies for moving existing analytical test methods to newer technologies within site, site to site Challenges during technology transfer of validated test methods site to site How to avoid some common pitfalls? 2

3 Existing Test Methods to New Technologies For Biological assays Steps within the assay process not necessarily replacing the assay Manual operation to automation such as: plaque counting sample diluting pipetting labeling For Microbiology assays Sterility direct to rapid 3

4 Existing Test Methods to New Technologies New Challenges Developing technology support Equipment, Automation Building expertise and skill Finding unexpected problems Developing implementation strategy regulatory approvals and product release Meeting expectations! is release time faster? Risks and Impact to change in the current laboratory environment Resource constraints training & testing Potential delay in product release 4

5 Technology Transfer of Validated Methods Top challenges Method developed and validated on equipment model not current new model, different factory settings Method not optimized since first developed High variability Assay acceptance criteria based on limited data Standard Operating Procedures not clear Assay process not lean 5

6 How to avoid some common pitfalls? Good Scientific Practice Team Agreement who is the team? Review Method Validation Process Assay Development Analytical Procedures Pre-validation, Optimization, Qualification Determine sources of variability Understand method Parameters Characterization studies Good Documentation Practices 6

7 Good Scientific Practices Assay Development Scientifically sound and appropriate Repeatable Robust Good Documentation Practice Real time documentation Clear to follow methods Training Data Verified/Reviewed Calculations transparent Reproducible 7

8 Team all the right people? Groups Analytical Development Quality Laboratories Technical Experts Statisticians Marketing? Regulatory! Site to Site (Team agreement critical otherwise project can get derailed) 8

9 Team Agreement Quality Stakeholders Scientists AD /QC/SME/ Statisticians 9

10 Review of Method Validation Process Assay Development Analytical Procedure Prevalidation/ Optimization Qualification/ Method Validation Revalidation Check the necessary conditions for Methods, Material Standards, Controls, Reagents Equipment, Instrumentation 10

11 Assay Development Subject Matter Experts /Cross functional team Analytical Development QC Laboratory Technology Manufacturing Engineering Automation/IT QA Method & Materials Multivariate experiments Assay Development Standards, Controls & Reagents Equipment & Instrumentation Project Plan - monitor progress Organize documents 11

12 Analytical Procedure Stepwise instructions Clear process flow Equipment set up, operating parameters Reagents, Reference/Standard preparation, special handling, expiry date Sample preparation critical aspects? System Suitability criteria Assay acceptance criteria Calculations Data Reporting data forms, self directed, prompts 12

13 Pre-validation, Optimization, Qualification Equipment/ Instrument Laboratory environment (temp, humidity) Handling of Sample, Reference & Reagent Training Determine Sources of Method Variation Understand Method Parameters System suitability Assay acceptance Reference & reagent qualifications Assay critical parameters Automation Accelerated/Stability Studies Degradation studies Identity, Purity, etc. Characterization Studies & Analyses Good Documentation Practices Organization of raw data, notebooks, etc. Data verification Test method Roadmap Procedure visual guidance Data documentation sheets/forms 13

14 Determine Sources of Variation Sample Source of material Research material, clinical material, process validation, Handling conditions Storage, bench top handling, thawing process, equilibrating process Preparation Dilution automated pipetting? liquid handling system? Mixing 14

15 Determine Sources of Variation Standards, Controls, Reagents General handling Storage conditions, e.g. light sensitive? thawing process, equilibrating process, e.g. room temperature, water bath/incubator Vendor changes Grade changes Preparation Mixing Expiry date (freshly prepared?) 15

16 Determine Sources of Variation 16 Equipment, Instrumentation Qualified, calibrated Model changes/upgrades? Example: Automated pipetting, Moisture analysis Vendor changes Example: Chromatography columns, capillaries Technical differences? Example: Spectrophotometer dual beam, single beam, diode array Laboratory Environment Humidity control, Temperature control

17 Determine Sources of Variation Training Resources - Trainers Subject Matter Experts maybe located off-site Turnover laboratory personnel and contractors Challenges to sustain cohesive training plan after implementation 17

18 Understand Method Parameters System Suitability Criteria System Suitability Standard Define optimal settings e.g. Chromatography assays flow rate, column temperature, run time, detector settings Generally based on small data set Assay Acceptance Criteria Reference Standard/Material Qualification Periodic/real time control charts, monitor drift 18

19 Understand Method Parameters Automation check Parameters set upon qualification Monitor system breakdown Monitor system upgrades Raw Data Server LIMS LIMS Link 19

20 Good Documentation Practices Test method Provides roadmap Controls changes Provides visual guidance, where necessary Data documentation forms/sheets Clear, self directed Raw data and notebooks Data verification 20

21 in a nutshell Ensure Good Scientific Practices Team Agreement, engagement and support from project planning, knowledge transfer, troubleshooting to reagent supply, equipment operation/maintenance, automation Review Method Validation Process Assay Development new or process improvement Analytical Procedures key to consistent execution Pre-validation, Optimization, Qualification Determine sources of variability monitor, review Understand Method Parameters monitor, review Characterization studies help in troubleshooting Good Documentation Practices ALWAYS! 21

22 Regulatory Guidance Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics (Feb 2014) Guidance for Industry: Analytical Procedures and Methods Validation (Aug 2000) Guidance for Industry: Submitting Samples and Analytical Data for Methods Validation (Feb 1997) Content and Format of Investigation New Drug Applications (INDs) for Phase I Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. IND Meetings for Human Drugs and Biologics, Chemistry, Manufacturing, and Controls Information. Q2A: Text on Validation of Analytical Procedures (Mar 1995) Q2B: Validation of Analytical Procedures: Methodology (Nov 1996) Q6A, Q6B: Specifications (Dec 2000, Aug 1999) Q8 (R2): Pharmaceutical Development (Nov 2009) Q9: Quality Risk Management (Jun 2006) Q10: Pharmaceutical Quality System (Apr 2009) EMEA Guidance on Validation of Analytical Procedures: Text and Methodology 22

23 Expectation It is the responsibility of the applicant to choose the validation procedure and protocol most suitable of their product. The main objective of validation of an analytical procedure is to demonstrate that the procedure is suitable for its intended purpose. Well characterized reference materials, with documented purity should be used throughout the validation study. The degree of purity necessary depends on the intended use. All relevant data collected during validation and formulae used for calculating validation characteristics should be submitted and discussed as appropriate 23

24 Note New Analytical & Method Validation Guidance explicit on: Lines , If an analytical procedure can only meet the established system suitability requirements with repeated adjustments to the operating conditions stated in the analytical procedure, the analytical procedure should be reevaluated, revalidated, or amended, as appropriate. EMEA Guidance: Section 6.4: Quality Control personnel should have access to production areas for sampling and investigation as appropriate. 24

25 25 THANK YOU!

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP Analytical Method Transfer Program Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP Outline Requirements for an AMT Program Develop Your AMT Program Qualify Your AMT Program On-going

More information

Analytical Procedures and Methods Validation for Drugs and Biologics

Analytical Procedures and Methods Validation for Drugs and Biologics Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA

More information

Analytical Procedures and Methods Validation for Drugs and Biologics

Analytical Procedures and Methods Validation for Drugs and Biologics Analytical Procedures and Methods Validation for Drugs and Biologics Lucinda (Cindy) Buhse, Ph. D. Acting Director, Office of Testing and Research Office of Pharmaceutical Science CDER, FDA CHPA Quality

More information

Regulatory Perspective on Analytical Method Validation During Product Development

Regulatory Perspective on Analytical Method Validation During Product Development Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author

More information

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION 1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS

More information

Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective

Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh

More information

5 KEY STEPS TO A SUCCESSFUL LABORATORY RELOCATION

5 KEY STEPS TO A SUCCESSFUL LABORATORY RELOCATION 5 KEY STEPS TO A SUCCESSFUL LABORATORY RELOCATION Author: John Best Global Relocation Services Leader PerkinElmer, Inc. GET STARTED Relocating a laboratory, whether down the hall or to another continent,

More information

Overview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only

More information

Analytical Methods Development and Validation

Analytical Methods Development and Validation Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the

More information

Basic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D

Basic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D Basic Good Laboratory Practice Christopher Jerome, B.Vet.Med., Ph.D Goals Outline the concept of Good Laboratory Practice (GLP) Provide some specific guidelines applicable to day to day work in the laboratory

More information

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP USP ICH Q2(R1) A Primer GxP cgmp PIC/S SOP ISO 17025 QA/QC LOD/LOQ API EP Validation of Analytical Methods FDA OECD GCP Validation of Analytical Methods Ludwig Huber Contents Preface...............................................

More information

The long anticipated draft of the FDA s

The long anticipated draft of the FDA s This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus

More information

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization

More information

Laboratory Reagents. for life science research.

Laboratory Reagents. for life science research. Laboratory Reagents Research, quality control, or routine analysis whatever the field of activity, where there is a need for laboratory reagents, Thermo Fisher Scientific has a suitable product. We offer

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS

FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability

More information

Breaking the Silo Mentality Working With Opinion Leaders

Breaking the Silo Mentality Working With Opinion Leaders CBI s 2 nd Annual KOL Conference Breaking the Silo Mentality Working With Opinion Leaders Kashif Chaudhry Objectives Share a view on the changing environment impacting the pharmaceutical industry and KOL

More information

Agilent solutions for contract research and manufacturing organizations

Agilent solutions for contract research and manufacturing organizations Agilent solutions for contract research and manufacturing organizations Cooperation between pharmaceutical companies and contract research organizations A successful approach to increasing efficiency along

More information

CDASH Clinical Data Acquisition Standards Harmonization

CDASH Clinical Data Acquisition Standards Harmonization CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future

More information

Subject Index. chromatography step, 125-

Subject Index. chromatography step, 125- A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade

More information

GDRP Guideline. Reliable Results for Density and Refractive Index

GDRP Guideline. Reliable Results for Density and Refractive Index GDRP Guideline GDRP TM Limit risks Minimize errors Improve quality Reduce costs Protect your investment Reliable Results for Density and Refractive Index Improve Lab Processes GDRP What is it Exactly?

More information

Symphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results

Symphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results Symphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results Precision Genomics for Immuno-Oncology www.personalis.com info@personalis.com 1 855-GENOME4

More information

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance

More information

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing

More information

for IND and RDRC Regulated PET Compounding

for IND and RDRC Regulated PET Compounding Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada

More information

Early Development Best Practices for Stability- Regulatory Perspective

Early Development Best Practices for Stability- Regulatory Perspective Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment

More information

Reducing Risk and Costs in the Global Supply Chain

Reducing Risk and Costs in the Global Supply Chain Reducing Risk and Costs in the Global Supply Chain Global Quality & Compliance Services for the Life Sciences Industry sensitech.com @sensitech Protecting the Life Sciences Supply Chain Can Be Costly Maintaining

More information

Qualification of High-Performance Liquid Chromatography Systems

Qualification of High-Performance Liquid Chromatography Systems Qualification of High-Performance Liquid Chromatography Systems L. Huber Hewlett- Packard GmbH, Waldbronn December 1998 Manuscript of an article published in BioPharm, Vol 11 Number 11, November 1998,

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances

More information

Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014

Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014 Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014 Introduction EU Clinical Trials Directive 2001 came into existence in the UK in May 2004 (Part 6 Manufacture of Investigational

More information

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.

More information

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,

More information

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp

More information

PMDA Perspective: Regulatory Updates on Process Validation Standard

PMDA Perspective: Regulatory Updates on Process Validation Standard CMC Strategy Forum Japan 2014 Tokyo, Japan, December 8-9, 2014 PMDA Perspective: Regulatory Updates on Validation Standard Kazunobu Oyama, PhD Office of Cellular and Tissue-based Products PMDA, Japan Disclaimer:

More information

COMMERCIAL PRODUCT STABILITY

COMMERCIAL PRODUCT STABILITY COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities) May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological

More information

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development

More information

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental

More information

Recent FDA Inspection Findings and Trends

Recent FDA Inspection Findings and Trends Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11

More information

Introduction to 21 CFR 11 - Good Electronic Records Management

Introduction to 21 CFR 11 - Good Electronic Records Management INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article Introduction to 21 CFR 11 - Good Electronic Records Management Pal Tapas Kumar* and Maity Subhasis NSHM Knowledge Campus,

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018

A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 Laboratory Name: Appendix Name: Appendix Number: Assessor: Date: Rev. 4.1 CALA CHECKLIST FOR MICROBIOLOGY Item 01 SAMPLING AND SAMPLE

More information

Strategies for Risk Based Validation of Laboratory Systems

Strategies for Risk Based Validation of Laboratory Systems Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,

More information

QUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY

QUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY QUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC

More information

Stability of Biological Products

Stability of Biological Products Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth

More information

Physicists Quality Control for MR Equipment

Physicists Quality Control for MR Equipment Physicists Quality Control for MR Equipment Geoffrey D. Clarke, Ph.D. University of Texas Health Science Center at San Antonio 1 Overview ABR and the role of the Qualified Medical Physicist/ MR Scientist

More information

Supplies and Reagents

Supplies and Reagents Supplies and Reagents PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 NHLBI-sponsored PACT Group Guidance for Industry INDs Approaches to Complying with CGMP During

More information

ICH Q11 Development & manufacture of drug substances

ICH Q11 Development & manufacture of drug substances ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical

More information

Conducting Supplier Audits: Ensure Validation Compliance

Conducting Supplier Audits: Ensure Validation Compliance Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why

More information

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852 22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:

More information

A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION

A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX

More information

Replacing Analytical Methods for Release and Stability Testing CBER Perspective

Replacing Analytical Methods for Release and Stability Testing CBER Perspective Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood

More information

Facility and Equipment Maintenance

Facility and Equipment Maintenance Facility and Equipment Maintenance Deborah L. Griffin Manager, Quality Assurance for Cellular Therapies Hillman Cancer Center University of Pittsburgh Cancer Institute University of Pittsburgh Medical

More information

USP <1116> and Contamination

USP <1116> and Contamination USP and Contamination Recovery Rates Scott Sutton ABSTRACT United States Pharmacopeia (USP) "Microbiological Control and Monitoring of Aseptic Processing Environments" approaches analysis

More information

Job Title: Cell Culture Technician (open June 1 through Oct 31, 2016)

Job Title: Cell Culture Technician (open June 1 through Oct 31, 2016) Rockland Immunochemicals Inc. is recognized as one of the world's leading manufacturers and suppliers of immunochemical reagents for basic research and discovery. Rockland Immunochemicals provides reagents

More information

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development - ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,

More information

Analytical and formulation attributes

Analytical and formulation attributes Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding

More information

Phase Appropriate Method Validation

Phase Appropriate Method Validation Phase Appropriate Method Validation Aryo Nikopour Irvine, California January 12, 2017 The Southern California Pharmaceutical Discussion Group (SCPDG) of AAPS OUTLINE What is Validation Guidelines Method

More information

European Medicines Agency Evaluation of Medicines for Human Use

European Medicines Agency Evaluation of Medicines for Human Use European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL

More information

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June

More information

OMPQ Update: Quality Systems and Drug Lifecycle Risk Management

OMPQ Update: Quality Systems and Drug Lifecycle Risk Management OMPQ Update: Quality Systems and Drug Lifecycle Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing & Product Quality FDA/CDER/OC FDA Inspections Summit October 22, 2014

More information

Validation Strategies for Equipment from Multiple Vendors

Validation Strategies for Equipment from Multiple Vendors Welcome to our E-Seminar: Validation Strategies for Equipment from Multiple Vendors Page 1 Content FDA guidelines and inspectional observations Validation & Qualification Approaches Instrument Qualification

More information

RADON MEASUREMENT OA - PRACTICE vs PROTOCOLS

RADON MEASUREMENT OA - PRACTICE vs PROTOCOLS RADON MEASUREMENT OA - PRACTICE vs PROTOCOLS Raymond Johnson, Sandy Colon, and Douglas Heim, Key Technology, Inc. Jonestown, PA ABSTRACT The EPA radon measurement device protocols of July 1992 specify

More information

Laboratory Data Collection, Analysis, Interpretation and Management

Laboratory Data Collection, Analysis, Interpretation and Management Laboratory Data Collection, Analysis, Interpretation and Management Agenda Overview of OpenLAB (CDS, ELN, ECM) OpenLAB CDS Remote Control (AIC) OpenLAB Collaboration (remote access) OpenLAB Demo Wrap up

More information

Library Guide: Active Pharmaceutical

Library Guide: Active Pharmaceutical Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the

More information

Risk-based Approach to Part 11 and GxP Compliance

Risk-based Approach to Part 11 and GxP Compliance Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!

More information

The validation of biological Active Pharmaceutical

The validation of biological Active Pharmaceutical This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements

More information

COURSE LISTING. Courses Listed. with Business Intelligence (BI) Crystal Reports. 26 December 2017 (18:02 GMT)

COURSE LISTING. Courses Listed. with Business Intelligence (BI) Crystal Reports. 26 December 2017 (18:02 GMT) with Business Intelligence (BI) Crystal Reports Courses Listed BOC345 - SAP Crystal Reports 2011: Optimizing Report Data Processing BOC320 - SAP Crystal Reports: - BOCE10 - SAP Crystal Reports for Enterprise:

More information

Regulatory Review Considerations of Drug-Linker Quality in ADCs

Regulatory Review Considerations of Drug-Linker Quality in ADCs Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions

More information

Zydus Hospira Oncology Pvt. Ltd.

Zydus Hospira Oncology Pvt. Ltd. Company, Position & Person Profile Zydus Hospira Oncology Pvt. Ltd. 6/7/15 About Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Private Limited (ZHOPL) is a joint venture company in Ahmedabad,

More information

Florida Department of TRANSPORTATION Materials Acceptance and Certification (MAC) System

Florida Department of TRANSPORTATION Materials Acceptance and Certification (MAC) System Materials Acceptance and Certification (MAC) System FTBA 2/11/2014 Presented By David Davis, Susan Blazo 1 The 5 W s Business Perspective Who will be affected by MAC Asphalt Production Facility QC Managers

More information

Enhancement will increase speed and accuracy of data collection during sample preparation. Additional space is needed for HCR scope testing

Enhancement will increase speed and accuracy of data collection during sample preparation. Additional space is needed for HCR scope testing NUMBER CC01398 2016 CHANGE CATEGORY Major Software REQUESTED CHANGE REASON FOR CHANGE IMPACT APPROXIMATE DATE IMPLEMENTED BET Uniflow system enhancement to allow batch data collection for Prep device,

More information

Most products in discovery

Most products in discovery FOCUS ON... OUTSOURCING Accelerating Bioassay Transfer in a GMP Environment by Ana T. Menendez Most products in discovery by pharmaceutical companies today are biopharmaceuticals. Made by living organisms,

More information

Zydus Hospira Oncology Pvt. Ltd.

Zydus Hospira Oncology Pvt. Ltd. Company, Position & Person Profile Zydus Hospira Oncology Pvt. Ltd. 6/7/15 About Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Private Limited (ZHOPL) is a joint venture company in Ahmedabad,

More information

Invisible Ink in GLP and GCP Research

Invisible Ink in GLP and GCP Research http://www.colginconsulting.com/invisible-ink-in-glp-and-gcp-research/ Invisible Ink in GLP and GCP Research What follows is more or less a transcript of my presentation at the annual meeting of the Pacific

More information

Contents. Contents (13) 1 Production (23)

Contents. Contents (13) 1 Production (23) 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing

More information

Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods

Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility,

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Review Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C

More information

Modeling Your Water Balance

Modeling Your Water Balance Modeling Your Water Balance Purpose To model a soil s water storage over a year Overview Students create a physical model illustrating the soil water balance using glasses to represent the soil column.

More information

Validation of Impurity Methods, Part I

Validation of Impurity Methods, Part I 626 LCGC NORTH AMERICA VOLUME 21 NUMBER 7 JULY 2003 www.chromatographyonline.com Validation Viewpoint John D. Orr, Ira S. Krull, and Michael E. Swartz This column is the first installment in a two-part

More information

Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation

Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation Christina Capacci-Daniel, Ph.D. Consumer Safety Officer / Acting Quality Assessment

More information

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials 14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal

More information

Latest USP Initiatives: Monographs, General Chapters, and Compounding

Latest USP Initiatives: Monographs, General Chapters, and Compounding Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical

More information

BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE

BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting

More information

Examples of regulatory expectations for analytical characterization and testing

Examples of regulatory expectations for analytical characterization and testing Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?

More information

NADERI ENGINEERING, INC.

NADERI ENGINEERING, INC. BIO-PHARMACEUTICAL ENGINEERING & VALIDATION CAPABILITIES "Cost Effective Solutions Through Innovation" 1240 Powell Street, Suite 2-B Emeryville, CA 94608 Tel: (510) 547-4040 Fax: (510) 547-4141 Website:

More information

Calibration in the Laboratory

Calibration in the Laboratory IVT Validation Week 2015 Calibration in the Laboratory 2015 The Lanese Group, Inc. Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Outline Overview of laboratory data integrity Elements of the Laboratory Instrument

More information

Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products

Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT

More information

LEGAL REQUIREMENTS FOR STABILITY

LEGAL REQUIREMENTS FOR STABILITY BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program

More information

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering

More information

Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220

Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220 Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure

More information

Terms of Reference Governance Committee

Terms of Reference Governance Committee 1. Purpose Terms of Reference Governance Committee The Governance Committee is responsible for ensuring that BC Assessment and its Board develop and implement an effective approach to corporate governance.

More information

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer

More information

INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW

INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute

More information

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs

More information